Ticker > Company >

Emcure Pharma share price

Emcure Pharmaceuticals Ltd.

NSE: EMCURE BSE: 544210 SECTOR: Pharmaceuticals & Drugs  62.23 K   48   23

1385.00
-15.70 (-1.12%)
NSE: Today, 11:14 AM

Price Summary

Today's High

₹ 1440.7

Today's Low

₹ 1374.3

52 Week High

₹ 1580

52 Week Low

₹ 889

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

26246.91 Cr.

Enterprise Value

26888.48 Cr.

No. of Shares

18.95 Cr.

P/E

65.7

P/B

8.37

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  165.44

CASH

13.8 Cr.

DEBT

655.37 Cr.

Promoter Holding

77.91 %

EPS (TTM)

₹  21.08

Sales Growth

25.28%

ROE

12.86 %

ROCE

15.41%

Profit Growth

97.18 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Emcure Pharmaceuticals Ltd.

Orofer Bevon Zostum Ferium Exhep Metpure Maxtra Pause

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year25.28%
3 Year8.96%
5 Year13.02%

Profit Growth

1 Year97.18%
3 Year-10.8%
5 Year12.6%

ROE%

1 Year12.86%
3 Year10.18%
5 Year14.62%

ROCE %

1 Year15.41%
3 Year12.43%
5 Year15.58%

Debt/Equity

0.2175

Price to Cash Flow

47.01

Interest Cover Ratio

4.7863

CFO/PAT (5 Yr. Avg.)

1.89410486876457

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 77.91 0.04
Mar 2025 77.92 0.04
Dec 2024 77.94 0.00
Sep 2024 78.08 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 749.255 Cr.
  • Company’s PEG ratio is 0.742353175778216.
  • The company has an efficient Cash Conversion Cycle of -22.6333 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.89410486876457.
  • The company has a high promoter holding of 77.91%.

 Limitations

  • The company has shown a poor profit growth of -10.7988930013688% for the Past 3 years.
  • The company has shown a poor revenue growth of 8.96135592274436% for the Past 3 years.
  • The company is trading at a high PE of 65.7.
  • The company is trading at a high EV/EBITDA of 31.383.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 970.29 1104.63 1028.81 1278.19 1096.57
Total Expenditure 850.54 952.47 904.4 1033.55 868.57
Operating Profit 119.75 152.16 124.42 244.64 228
Other Income 27.94 54.93 19.41 22.4 21.52
Interest 37.57 31.4 19.93 24.07 20.54
Depreciation 55.08 56.34 56.65 56.91 59.82
Exceptional Items 0 0 0 0 -3.5
Profit Before Tax 55.05 119.36 67.25 186.05 165.67
Tax 14.6 32.44 17.05 46.5 42.88
Profit After Tax 40.45 86.92 50.2 139.56 122.79
Adjusted EPS (Rs) 2.23 4.6 2.65 7.37 6.48

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 3153.66 3387.24 3107.09 3497.66 4381.92
Total Expenditure 2410.26 2592.57 2668.59 3055.76 3758.76
Operating Profit 743.41 794.67 438.49 441.89 623.17
Other Income 111.91 132.68 125.35 138.26 142.48
Interest 123.34 145.14 166.83 166.09 112.96
Depreciation 156.24 165.79 178.52 204.83 224.97
Exceptional Items -18.29 0 -6.15 -9.32 0
Profit Before Tax 557.45 616.42 212.34 199.91 427.71
Tax 136.97 169.61 52.28 39.08 110.58
Net Profit 420.48 446.81 160.06 160.83 317.13
Adjusted EPS (Rs.) 23.25 24.71 8.85 8.88 16.74

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 180.85 180.85 180.85 181.15 189.48
Total Reserves 2120.92 1531.68 1661.02 1753.95 2834.88
Borrowings 645.97 512.4 600.65 438.21 406.29
Other N/C liabilities 126.27 164.19 177 253.51 266.3
Current liabilities 1789.18 1934.06 1996.33 2130.12 1719.16
Total Liabilities 4863.2 4323.18 4615.85 4756.93 5416.11
Assets
Net Block 1277.9 1307.36 1432.71 1718.24 1759.06
Capital WIP 192.09 239.25 253.1 106.4 92.83
Intangible WIP 0 0 0 0 6.28
Investments 863.73 563.36 690.02 684 677.65
Loans & Advances 299.42 63.25 77.51 105.37 393.13
Other N/C Assets 27.38 13.92 23.01 24.91 27.11
Current Assets 2202.68 2136.05 2139.51 2118.01 2460.05
Total Assets 4863.2 4323.18 4615.85 4756.93 5416.11
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 557.45 616.42 212.34 199.91 427.71
Adjustment 246.72 265 309.21 325.56 284.14
Changes in Assets & Liabilities 84.38 -283.04 68.37 126.36 -87.45
Tax Paid -113.67 -170.67 -84.54 -66.86 -66.11
Operating Cash Flow 774.87 427.71 505.37 584.97 558.29
Investing Cash Flow -835.78 -393.81 -270.56 -173.08 -437.66
Financing Cash Flow 30.97 -342.96 -54.52 -287.75 -49.25
Net Cash Flow -29.94 -309.06 180.3 124.15 71.38

Corporate Actions

Investors Details

PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 78.08 77.94 77.92 77.91
bhavana satish mehta 4.72 4.71 4.71 4.71
everest trust (shares hel... 7.68 7.67 7.66 7.66
girish harrai desai 0.06 0.06 0.06 0.06
kamini sunil mehta 0.88 0.88 0.88 0.88
namita vikas thapar 2.68 2.68 2.68 2.68
niraj sunil mehta 0.58 0.58 0.58 0.58
pushpa rajnikant mehta 2.06 2.05 2.05 2.05
ranjanakumari mukeshbhai ... 0.02 0.02 0.02 0.02
rutav sunil mehta 0.52 0.52 0.52 0.52
samit s mehta 7.16 7.15 7.14 7.14
sanjay rajanikant mehta 1.96 1.96 1.95 1.95
satish r mehta 39.87 39.80 39.79 39.79
shaila sharad gujar 0.04 0.04 0.04 0.04
smita paresh shah 0.07 0.07 0.07 0.07
suhasinee saumil shah 0.07 0.07 0.07 0.07
sunil rajanikant mehta 1.51 1.50 1.50 1.50
surekha umakant shah 0.17 0.17 0.17 0.17
swati hetalkumar shah 0.03 0.03 0.03 0.03
unity trust (shares held ... - - - 7.66
vikas m thapar 0.34 0.34 0.34 0.34
unity trust (shares held ... 7.67 7.66 7.66 -
PARTICULARS Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 21.92 22.06 22.08 22.09
bc investments iv limited... 8.69 8.68 8.68 8.67
llp - 0.08 0.07 0.04

Annual Reports

Title Link
Title Link
 No Annual reports exist for this company.Report us

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE RATINGS
Credit CARE RATINGS
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q3FY25
Concall Q1FY25
TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Presentation related to this company.Report us

Company News

Emcure Pharmaceuticals informs about outcome of board meeting 7 Aug, 2:57 PM Emcure Pharma - Quaterly Results 7 Aug, 1:42 PM Emcure Pharmaceuticals enters into agreement with Sanofi India 17 Jul, 9:21 AM USFDA concludes PAI at Emcure Pharmaceuticals’ Gujarat manufacturing facility 10 Jul, 10:11 AM Emcure Pharmaceuticals incorporates wholly owned subsidiary 4 Jul, 6:06 PM Emcure Pharmaceuticals informs about incorporation of WOS 4 Jul, 5:21 PM Emcure Pharmaceuticals gets nod to incorporate wholly owned subsidiary 21 Jun, 5:22 PM Emcure Pharmaceuticals informs about updates 21 Jun, 4:21 PM Emcure Pharmaceuticals informs about press release 21 Jun, 4:14 PM Emcure Pharmaceuticals informs about acquisition 21 Jun, 3:38 PM Emcure Pharmaceuticals informs about outcome of board meeting 21 Jun, 2:05 PM Emcure Pharmaceuticals gets nod for acquiring 20.42% stake of Zuventus Healthcare 21 Jun, 1:00 PM Emcure Pharmaceuticals inks pact to purchase electricity generated from TUPL 3 Jun, 12:00 PM Emcure Pharmaceuticals gets nod to incorporate wholly-owned subsidiary 23 May, 9:27 AM Emcure Pharmaceuticals informs about change in management 22 May, 5:00 PM Emcure Pharma - Quaterly Results 22 May, 2:28 PM Emcure Pharma - Quaterly Results 22 May, 2:28 PM Emcure Pharma - Quaterly Results 22 May, 2:28 PM Emcure Pharmaceuticals gets EIR for Pune manufacturing facility 21 Apr, 10:22 AM Emcure Pharmaceuticals’ arm inks pact with Manx Healthcare 4 Apr, 3:45 PM Emcure Pharmaceuticals’ arm inks in-licensing agreement with WiQo 2 Apr, 12:39 PM Emcure Pharmaceuticals expands OTC Portfolio with Arth Supplements 10 Mar, 5:45 PM Emcure Pharma - Quaterly Results 6 Feb, 3:04 PM Emcure Pharma - Quaterly Results 6 Feb, 3:04 PM Emcure Pharmaceuticals informs about press release 23 Jan, 5:36 PM Emcure Pharmaceuticals inaugurates R&D centre in Gujarat 23 Jan, 3:45 PM Emcure Pharmaceuticals informs about compliance certificate 10 Jan, 12:46 PM Emcure Pharmaceuticals informs about newspaper publication 23 Nov, 11:38 AM Emcure Pharma - Quaterly Results 7 Nov, 3:41 PM Emcure Pharma - Quaterly Results 7 Nov, 3:41 PM Emcure Pharma - Quaterly Results 7 Nov, 3:41 PM Emcure Pharmaceuticals informs about press release 3 Oct, 12:53 PM Emcure Pharmaceuticals signs agreement with Gilead Sciences Ireland UC 3 Oct, 11:30 AM Emcure Pharmaceuticals informs about closure of trading window 26 Sep, 4:32 PM Emcure Pharmaceuticals gets nod to incorporate wholly-owned subsidiary 14 Sep, 3:03 PM Emcure Pharma - Quaterly Results 13 Aug, 9:13 PM Emcure Pharmaceuticals signs Power Purchase Agreement with Sunsure Energy 26 Jul, 10:41 AM Emcure Pharmaceuticals coming with IPO to raise Rs 1993.05 crore 29 Jun, 3:56 PM Emcure Pharmaceuticals gets SEBI's go-ahead to launch IPO 15 Dec, 12:36 PM

Emcure Pharma Stock Price Analysis and Quick Research Report. Is Emcure Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Emcure Pharma and its performance over the period of time. Emcure Pharma stock price today is Rs 1379.4.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Emcure Pharma cash from the operating activity was Rs 558.285 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Emcure Pharma has a Debt to Equity ratio of 0.2175 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Emcure Pharma , the EPS growth was 88.5081 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Emcure Pharma has OPM of 14.221287270158 % which is a bad sign for profitability.
     
  • ROE: Emcure Pharma have a average ROE of 12.8618 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Emcure Pharma is Rs 1379.4. One can use valuation calculators of ticker to know if Emcure Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Emcure Pharma
X